AMRX Amneal Pharmaceuticals Inc

Price (delayed)

$4.83

Market cap

$1.45B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$3.92B

Highlights
The company's gross profit rose by 40% YoY
AMRX's quick ratio is up by 32% YoY and by 6% from the previous quarter
The company's net income has shrunk by 119% QoQ but it has surged by 91% YoY
AMRX's EPS has dropped by 118% since the previous quarter but it has soared by 93% year-on-year

Key stats

What are the main financial stats of AMRX
Market
Shares outstanding
300.84M
Market cap
$1.45B
Enterprise value
$3.92B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.48
Price to sales (P/S)
0.36
EV/EBIT
30.88
EV/EBITDA
10.89
EV/Sales
1.97
Earnings
Revenue
$1.99B
EBIT
$126.86M
EBITDA
$359.71M
Free cash flow
$410.94M
Per share
EPS
-$0.11
Free cash flow per share
$2.78
Book value per share
$1.08
Revenue per share
$13.43
TBVPS
$14.69
Balance sheet
Total assets
$3.96B
Total liabilities
$3.59B
Debt
$2.92B
Equity
$323.02M
Working capital
$922.88M
Liquidity
Debt to equity
9.04
Current ratio
2.45
Quick ratio
1.55
Net debt/EBITDA
6.85
Margins
EBITDA margin
18.1%
Gross margin
32%
Net margin
-0.9%
Operating margin
4%
Efficiency
Return on assets
-0.4%
Return on equity
-5.6%
Return on invested capital
3.1%
Return on capital employed
3.8%
Return on sales
6.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AMRX stock price

How has the Amneal Pharmaceuticals stock price performed over time
Intraday
0.42%
1 week
12.06%
1 month
-8.17%
1 year
8.3%
YTD
5.69%
QTD
-5.66%

Financial performance

How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$1.99B
Gross profit
$636.46M
Operating income
$79.27M
Net income
-$17.3M
Gross margin
32%
Net margin
-0.9%
The company's operating income has surged by 182% YoY but it fell by 13% QoQ
The operating margin has surged by 169% year-on-year but it has declined by 13% since the previous quarter
AMRX's net margin has dropped by 120% since the previous quarter but it has surged by 92% year-on-year
The company's net income has shrunk by 119% QoQ but it has surged by 91% YoY

Growth

What is Amneal Pharmaceuticals's growth rate over time

Valuation

What is Amneal Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.48
P/S
0.36
EV/EBIT
30.88
EV/EBITDA
10.89
EV/Sales
1.97
AMRX's EPS has dropped by 118% since the previous quarter but it has soared by 93% year-on-year
The price to book (P/B) is 7% lower than the last 4 quarters average of 4.8
Amneal Pharmaceuticals's equity has increased by 7% QoQ
AMRX's revenue is up by 18% year-on-year
The price to sales (P/S) is 10% lower than the last 4 quarters average of 0.4

Efficiency

How efficient is Amneal Pharmaceuticals business performance
Amneal Pharmaceuticals's return on equity has shrunk by 119% QoQ but it has surged by 91% YoY
The company's return on assets has shrunk by 118% QoQ but it has surged by 92% YoY
AMRX's ROS has dropped by 57% year-on-year and by 4.5% since the previous quarter
AMRX's ROIC is down by 48% YoY and by 3.1% from the previous quarter

Dividends

What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AMRX.

Financial health

How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 10% greater than its total liabilities
The company's current ratio rose by 33% YoY and by 7% QoQ
AMRX's quick ratio is up by 32% YoY and by 6% from the previous quarter
The company's debt to equity fell by 12% YoY and by 7% QoQ
AMRX's debt is down by 11% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.